After being fired, I became the light of medicine

Chapter 85 Will Qingshan Pharmaceutical agree to this price? (ask for monthly votes)
As he spoke, Zhou Hai pressed the projection pen again, and another detailed data chart appeared on the screen.

"Qingshan Pharmaceutical has not yet released this data to the public. You can take a closer look."

"There are a total of 98 subjects in the first batch of their Phase III clinical trial, including 49 in the control group and 49 in the experimental group."

"49 out of 47 patients in the trial group were cured, and the overall actual cure rate was as high as 95.98%!"

95.98%!

As soon as the words fell, all the leaders and experts present looked at the screen, with disbelief in their eyes.

In fact, many people present at the scene scoffed and even did not believe it when Tsingshan Pharmaceutical said that the Phase III clinical trial would achieve more than 90% cure!
But now, the effective cure rate of "Ekofovir" has not only exceeded 90%, but has reached an astonishing 95.98%!

This data can be used to publicize the complete cure of hepatitis B!
At this moment, Zhou Hai coughed lightly and pressed the projection pen again.

"The only two people out of the 49 who have not been cured are those who were infected with hepatitis B through mother-to-child transmission."

"Compared with patients who are infected later in life, it is more difficult to cure hepatitis B patients who are transmitted from mother to child. We have also communicated with Tsingshan Pharmaceutical on this matter.
They said they are trying to get the patient to continue taking the medicine for two months, and there is a high probability that the patient will be cured! ”

"That is to say, the actual cure rate of Qingshan Pharmaceutical's 'Acofenprofovir' has reached 100%, except for mothers and infants with hepatitis B."

100%! ! !

Many people in the conference room gasped. The 95.9% cure rate was surprising enough, but no one expected the final result to be - 100%!

Zhou Hai saw the expressions of the crowd, but he was not surprised because he had the same expression when he saw the clinical data two days ago.

He continued:

"Okay, now that everyone is very clear about the actual effect of this drug, let's officially get into today's topic."

"According to the terms of the 'Starlight Project', this drug will be included in our medical insurance procurement catalog once it is launched on the market."

"As we all know, there are a large number of hepatitis B patients in our country, and the impact is far-reaching. After this drug is included in the medical insurance, it will undoubtedly be a particularly huge expense for the medical insurance fund!"

"Therefore, we must conduct price research and analysis on this drug as soon as possible and give the comrades in the Medical Insurance Bureau a psychological bottom price so that they can have a clear idea of ​​the price when negotiating with Qingshan Pharmaceutical and have a certain negotiating initiative."

After the words fell, everyone nodded, and their expressions gradually became serious.

At this moment, a middle-aged man sitting in the front row of the conference table suddenly stood up. He first made an apologetic gesture to Zhou Hai, then turned around and looked at the people around him, bowed with both hands and said:
"Dear leaders, experts, and colleagues, I am Liu Weiguo from the Medical Insurance Bureau."

"Before we discuss this, I hope everyone can be kind and consider the difficulties faced by our Medical Insurance Bureau. We must set the expected price of this drug lower. Otherwise, we won't be able to come up with that much money even if we kill ourselves!"

The way he bowed made everyone laugh.

Of course, everyone could hear a hint of joking in Liu Weiguo's words. After all, today's seminar was just an official internal meeting, and what was discussed was only the psychological price. The final price would have to be determined after negotiations with Tsingshan Pharmaceutical.

but,

Everyone could also hear the helplessness and sadness in Liu Weiguo's words. Medical insurance expenditures have continued to increase over the years, and it is an indisputable fact that the medical insurance fund is in deficit.

The inclusion of "Ikeprofovir" in the medical insurance will inevitably result in a huge expenditure, which will undoubtedly make the situation worse.

"Okay, okay, definitely."

Everyone responded with a smile, and this interruption relaxed the originally tense atmosphere a lot, and the seminar gradually got back to the point.

This kind of seminar usually involves taking turns to speak, and after a while, the microphone fell into the hands of an older man.

Zhou Hai looked over and saw the nameplate in front of the old man’s conference table that read: Yao Haibo.

"Academician Yao, you are an expert in the field of biomedicine at the Chinese Academy of Sciences, and you have many years of experience in the research and development of innovative drugs and market promotion. Could you please tell me your opinion?"

"it is good."

Yao Haibo was not arrogant. He gently pushed up his glasses and said in a deep voice:
"Dear leaders and colleagues, after receiving the seminar notice yesterday afternoon, I collected some information and made a plan. Now I will tell you my ideas."

"First of all, since Qingshan Pharmaceutical has independently developed such an excellent innovative drug, we must first follow the market rules of innovative drugs and protect the economic interests of Qingshan Pharmaceutical."

"After all, everyone knows that the R&D of innovative drugs requires large investments and carries high risks, so it is understandable to recoup costs and make profits after success." "However, as Director Liu Weiguo said just now, we must also consider the affordability of the Medical Insurance Bureau, so..."

"I think we can refer to the current cost of Gilead's curing a hepatitis C patient in the country."

How much does it cost to cure a person with Hepatitis C?
Everyone nodded slightly. In 2019, "Sofosbuvir and Velpatasvir Tablets" under the name of Gilead Sciences of the United States, commonly known as "Gilead Third Generation", officially entered the national medical insurance, ushering in the era of comprehensive cure for hepatitis C.

Using existing similar drugs as reference is indeed a good idea.

Yao Haibo continued:

"Gilead's 'Gel III' only needs to be taken for three months, and the cost of the entire course of treatment after reimbursement is about 6000 yuan."

"Considering that there are only 1000 million hepatitis C patients in China, and 1.2 million hepatitis B patients, the unit price must be lower than that of 'Epclusa III'."

"I did a rough calculation and I think the cost of curing a hepatitis B patient should be around 2500 yuan."

"2500 yuan?"

As soon as he finished speaking, Liu Weiguo from the Medical Insurance Bureau waved his hand first.

"Academician Yao, this price is too expensive, 2500 yuan per person. Based on 1.2 million patients, that would be 3000 billion yuan in sales. Where does our medical insurance get so much money?"

Yao Haibo was not upset about being interrupted, and replied seriously:

"1.2 million patients is just a statistical caliber. In fact, a large number of patients will not seek treatment, at least not in the first place."

"So, I think it is more appropriate to calculate based on the base of 3000 million. 3000 million multiplied by 2500 yuan, Qingshan Pharmaceutical can have a sales amount of 750 billion. After deducting R&D expenses and other expenses, the profit is at least over billion."

"Of the 2500 yuan cost, 60% can be reimbursed by the national medical insurance, and the patient has to pay 40% out of pocket. In total, hepatitis B can be cured for 1000 yuan, a price that is absolutely acceptable to patients."

As soon as the words were spoken, everyone present agreed.

A drug earning more than 40 billion yuan in profits is already very considerable, and on the medical insurance side, patients bear 60% and medical insurance bears %, which is an acceptable threshold.

Only Liu Weiguo kept shaking his head.

"It's too expensive, it's too expensive..."

With Academician Yao’s speech setting the tone, the following discussion focused on a more in-depth discussion of Gilead’s “Gilead’s Third Generation” as a reference.

Perhaps because of Liu Weiguo's strong opposition, after half an hour of discussion, everyone finally set the standard of 2000 yuan to cure a hepatitis B patient as the psychological bottom price for medical insurance negotiations.

In other words, as long as the price of Qingshan Pharmaceutical's "Ekofovir" is no more than 1000 yuan per bottle, the Medical Insurance Bureau will accept it for inclusion in medical insurance.

Seeing that this seminar was about to be successfully completed, the host Zhou Hai couldn't help but smile:

"Dear leaders, you have all worked hard, but please remember the confidentiality clause and do not leak any information before the project is implemented."

"Yes, I know. I do have some awareness."

The atmosphere in the meeting room became cheerful, except for Liu Weiguo, deputy director of the Medical Insurance Bureau, who had a worried look on his face.

"Hey, let me ask you guys, do you want to discuss whether the psychological price of 2000 yuan can be lowered further? Where does our medical insurance fund get so much money?!"

"Haha, Director Liu, this price is not expensive. After all, it is an innovative drug, and the patient also bears part of the cost."

"That's right. Besides, this is a one-time cure. Once you get through the initial large expense, the subsequent expenses will be much less."

"Yes, you make it sound simple, but... there is still a question, will Qingshan Pharmaceutical agree to this price?"

……

PS: Thank you Mo Huantian for the 5000 coins reward! I will update after the game is released, so remember it!
Thank you for your monthly tickets. I feel your enthusiasm! Thank you!

(End of this chapter)